Inari Medical (NASDAQ: NARI) went public in what should have been one of the most difficult times for a non-COVID related healthcare company ever -- May 2020. Yet it has ridden the success of its clot-removing devices -- the FlowTriever and ClotTriever -- to 124% gains since.
With earnings coming up, it's a good time to reflect on the past few quarters and determine what investors should be focusing on in its next report. Aside from revenue growth, which everyone obsesses over, the key questions for management center on what investors can expect in a post-COVID world.
Image source: Getty Images.
For further details see:
3 Things I'm Looking For in Inari Medical's Earnings